Skip to content
Home/Companies/Biotech/Ariceum Therapeutics

Ariceum Therapeutics

Biotech·Germany·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Ariceum Therapeutics?

Ariceum Therapeutics is currently owned by Earlybird Venture Capital through Earlybird Health (2017 vintage), since 2023.

Hand-verified · updated 2026-08-10

Earlybird Venture Capital
Investor
Earlybird Venture Capital
Earlybird Health · 2017 · VC

Key facts

HQGermany
SectorBiotech
StatusActive

More from Earlybird Health

Other portfolio companies in the same fund.

Axon Vascular Europe
Active
MedTechUnited Kingdom· 2025
Haya Therapeutics
Haya Therapeutics
Active
BiotechSwitzerland· 2025
Hilo
Hilo
Active
MedTechSwitzerland· 2025
Portal Biotech
Active
BiotechUnited Kingdom· 2025
Rivia
Active
HealthTechSwitzerland· 2025
Gemma Biotherapeutics
Gemma Biotherapeutics
Active
BiotechUnited States· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Ariceum Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Ariceum Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue